Table 1

Presentation characteristics and univariate analyses of associations with disclosure time

Characteristics	COI display duration					Duration per disclosure
Characteristics	N	Median	IQR		Sig*	N	Median	IQR		Sig*
Gender
Male	1322	2.60	1.52	4.29	0.000	622	0.72	0.30	1.76	0.000
Female	351	2.20	1.30	3.47		84	1.31	0.51	6.92
Estimated age†
15–25	5	1.98	1.48	6.71	0.000	1	–	–	–	0.000
25–35	213	2.38	1.52	3.45		37	2.34	0.95	4.44
35–45	325	2.56	1.48	6.59		92	1.02	0.30	2.31
45–55	367	2.46	1.31	4.24		158	0.70	0.32	2.41
55–65	619	2.51	1.52	4.29		331	0.69	0.30	1.51
65–75	129	2.96	1.67	6.30		78	0.69	0.27	1.66
75–85	14	5.00	1.42	16.64		9	1.02	0.65	2.67
Region of location of the speaker’s institution
Northern Europe	294	3.06	1.68	4.92	0.000	138	1.20	0.63	3.16	0.000
Eastern Europe	74	2.04	1.26	3.27		27	0.55	0.14	0.99
Southern Europe	356	1.89	1.27	3.37		101	0.58	0.26	1.32
Western Europe	544	2.59	1.53	4.18		269	0.62	0.28	1.63
USA+Canada	208	3.43	1.91	6.27		136	0.86	0.38	2.71
Central+South America	19	2.49	1.58	3.81		4	2.52	0.70	3.07
Africa+East Asia	36	1.62	0.92	2.54		5	0.98	0.16	4.76
Asia	119	2.35	1.52	3.45		18	1.37	0.41	2.34
Australia+New Zealand	23	2.33	1.17	2.77		8	0.57	0.32	5.57
Subject type †
Guideline	90	2.07	1.28	3.31	0.039	46	0.38	0.17	1.50	0.000
Overview	576	2.66	1.48	4.48		323	0.65	0.29	1.50
Observational study	390	2.65	1.61	3.85		102	1.73	0.60	4.11
Experimental study	161	2.85	1.87	4.01		70	0.91	0.38	2.55
Case report	179	2.13	1.35	3.36		61	0.77	0.29	1.39
Informative talk	255	2.19	1.29	4.49		102	0.85	0.33	1.93
Systematic review	21	3.71	2.16	4.85		2	3.86	2.12	–
Subject of presentation‡
Commercial relevance	425	3.26	1.97	5.09	0.000	281	0.72	0.33	4.82	0.831
No commercial relevance	1246	2.26	1.36	3.78		425	0.79	0.30	1.92
Disclosures also presented on title slide
No	1618	2.54	1.49	4.15	0.000	687	0.79	0.32	1.96	0.031
Yes	55	1.64	1.01	2.30		19	0.42	0.26	0.88
Disclosures present†
Absent	948	2.00	1.27	3.20	0.000	–	–	–	–	–
Present (median # is 5)	724	3.44	2.00	6.27		706	0.78	0.32	1.94
Verbal disclosure§
No	536	1.31	0.93	1.86	0.000	175	0.39	0.22	0.97	0.000
Yes, ‘present’	1000	2.99	2.06	4.51		407	0.72	0.33	1.65
Yes, partially specified	102	11.11	6.58	15.54		90	1.75	0.81	4.10
Yes, complete	35	7.84	5.31	11.30		34	6.33	4.10	9.02
Commerciality of COI¶
Commercial COI	599	3.24	1.93	5.41	0.000	594	0.79	0.33	1.97	0.000
Non-commercial COI	29	4.80	2.63	14.34		29	3.67	1.85	10.26
Both	86	4.57	2.26	8.71		79	0.42	0.19	0.92
Type of COI**
Personal	111	3.07	2.02	5.31	0.600	107	1.65	0.44	3.13	0.000
Consultancy	108	3.21	1.85	4.88		108	1.23	0.61	3.21
Research	120	3.64	2.11	7.15		114	1.57	0.82	3.42
Any combination	378	3.51	1.96	5.27		367	0.49	0.25	0.99

*Significance level is the p value of the logarithmically transformed COI display duration.
†One missing value.
‡Two missing values.
§Presence of verbal disclosure is subdivided in no verbal disclosure; solely mentioning the presence or absence of disclosures; a partial specification of the disclosed COI (eg, ‘research funding’); or a complete verbal disclosure (eg, including pharmaceutical company names).
¶Commercial COIs are that with pharmaceutical or device companies; non-commercial disclosures are that with government funding or public funding.
**Personal disclosures are eg, lecture fees and travel support, consultancy disclosures include royalties, ownership and stockholdership.
COI, conflict of interest.